Aiforia as a company

Aiforia's business

Translating images into discoveries, decisions, and diagnoses

Aiforia aims to equip pathologists and scientists in preclinical and clinical laboratories with powerful deep learning artificial intelligence (AI) for medical image analysis. The company’s business model is based on providing versatile and scalable cloud-based software solutions as well as bespoke services for healthcare professionals to develop and deploy AI models to increase the speed, accuracy and consistency of analysing large and complex medical images. The AI model is able to bring precision and efficiency to evaluating images, beyond that of current capabilities.

Aiforia’s offering is divided into software solutions for the preclinical and clinical markets, covering scientists and pathologists across the whole span of the healthcare system. From solutions for medical research in aiding the rapid and accurate discovery of a novel biomarker of disease, to tools and services for organisations looking to cut costs and time on bringing drugs to market by providing tools to accelerate and standardise the preclinical study of novel molecules, to also offering clinical grade AI based tools for supporting pathologists in diagnosing diseases like breast cancer.

Preclinical market and product offering

The product offering consists of Aiforia Create, an agile solution with which the end user can develop their own AI model for any image analysis application simply by annotating images to train the AI model what to identify, quantify, or measure. No coding or dedicated hardware is required as the cloud based Aiforia Create is optimised for seamless use.

Aiforia Create provides a host of comprehensive tools in AI-based medical image analysis, such as the patented Annotation Assistant, which partially automates the training of AI models by the end user. Aiforia also offers Custom AI Services in which Aiforia’s expert scientists build bespoke AI models for customers based on their specific needs.

Aiforia has an established customer base in the preclinical research market; customers include those from well-known academic institutes and major pharmaceutical companies. So far over 400 AI models for preclinical research have been built with Aiforia Create for a wide range of diseases, for example: breast cancer, Parkinson’s disease, organ transplantation, liver diseases, inflammatory bowel diseases, and more.

Aiforia's users around
the world

Aiforia's cloud platform is used globally 

Aiforia Users - Report

3000+ users Pathologists, medical scientists,
and researchers use Aiforia's AI and
image analysis tools worldwide.
50+ countries Aiforia's cloud-based software and
services are used in over 50 countries
across the world.
1 million+ images Over 1 million images have been
analysed with Aiforia and 400+
AI models developed.

Clinical diagnostics market and product offering

Supported by its well-established technology and history in the preclinical market, Aiforia is now entering the clinical diagnostics market. Disease rates are increasing, thus more samples need to be analysed, creating a demand for new technologies to assist in the diagnosis of a wide range of diseases.

Aiforia is currently developing the Aiforia Clinical solution, a portfolio of tools for AI-supported diagnostics, intelligent visualisation of patient samples, as well as automated screening and reporting tools, to assist pathologists in the diagnosis of some of the world’s most prevalent cancers such as breast, lung and prostate cancer.

The CE-IVD marked Aiforia Clinical viewer for the clinical pathology workflow to enhance the analysis of images from tissue samples, especially in remote viewing and collaboration and the CE-IVD marked ki67 AI Model for the diagnostic support of breast cancer, are already commercialised. The company aims to bring a CE-IVD marked AI model for lung cancer diagnostics into the markets during the 2021. In addition, the company aims to obtain CE-IVD markings for other diagnosis-specific AI Models, such as prostate cancer, in the upcoming years.